Raltegravir
- Generic Name
- Raltegravir
- Brand Names
- Isentress
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O5
- CAS Number
- 518048-05-0
- Unique Ingredient Identifier
- 22VKV8053U
- Background
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
- Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Post-exposure prophylaxis for occupational exposure to HIV therapy
RAltegravir Switch STudy: Effects on Endothelial Recovery
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 24
- Registration Number
- NCT01453933
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Noord Holland, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
Renal Transplantation and Raltegravir in HIV-Infected Patients
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 27
- Registration Number
- NCT01453192
- Locations
- 🇫🇷
Hôpital Kremlin Bicêtre, Service de Néphrologie, Kremlin Bicêtre, France
🇫🇷Hôpital Henri Mondor, Service de Néphrologie Transplantation, Créteil, France
🇫🇷CHRU Lille, Service de néphrologie, Lille, France
A Key Link for Transmission Prevention
- Conditions
- Interventions
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 46
- Registration Number
- NCT01450189
- Locations
- 🇲🇼
Lighthouse Trust, Kamuzu Central Hospital, Lilongwe, Malawi
🇲🇼UNC Project, Lilongwe, Malawi
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
- Conditions
- Interventions
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- St Vincent's Hospital, Sydney
- Target Recruit Count
- 6
- Registration Number
- NCT01448486
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
The Effect of Intermittent Rifampicin on Raltegravir
- Conditions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Helen Reynolds
- Target Recruit Count
- 18
- Registration Number
- NCT01424826
- Locations
- 🇬🇧
Royal Liverpool & Broadgreen Univeristy Hospitals NHS Trust, Liverpool, United Kingdom
Study of Options for Second-Line Effective Combination Therapy (SELECT)
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2021-08-05
- Target Recruit Count
- 515
- Registration Number
- NCT01352715
- Locations
- 🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇲🇼University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi
🇿🇦Soweto ACTG CRS (12301), Johannesburg, South Africa
The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 19
- Registration Number
- NCT01335620
- Locations
- 🇬🇧
Chelsea & Westminster Hospital NHS Trust, London, United Kingdom
🇬🇧Imperial College Healthcare NHS Trust, London, United Kingdom
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 132
- Registration Number
- NCT01332227
- Locations
- 🇺🇸
Health For Life Clinic Pllc, Little Rock, Arkansas, United States
🇺🇸Eisenhower Medical Center, Palm Springs, California, United States
🇺🇸Consultive Medicine, Daytona Beach, Florida, United States
Levels of Raltegravir in the Female Genital Tissue
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 10
- Registration Number
- NCT01327482
- Locations
- 🇺🇸
University of Washington, Clinical Research Center, Seattle, Washington, United States
Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Angela Kashuba, PharmD
- Target Recruit Count
- 15
- Registration Number
- NCT01325051
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.